Join our daily newsletter At The Bell to receive exclusive market insights
- Uscom (UCM) has released its Ventitest Ventilator testing device
- The SpiroSonic Ventitest device uses ultrasonic technology to measure the pressure, flow and volume outputs of medical devices like ventilators
- The ventilator market has been flooded in recent months since COVID-19 hit the globe, and these devices require constant monitoring to stay effective
- The device the company has produced has been in testing and production for 15 years, giving a high degree of confidence in its efficacy
- Uscom shares are in the green today, trading 1.16 per cent higher for 21.8 cents
Uscom (UCM) has today released its SpiroSonic Ventitest ventilator test device, a new test device that measures the effectiveness of medical equipment such as COVID-19 tests.
The device uses Uscom’s spirometry technology to measure the measure the flow, pressure and volume outputs of respiratory assist devices such as ventilators, anaesthesia devices and home ventilation systems such as CPAP machines and respirators.
Over time, equipment like respirators, which pump prescribed volumes of air at certain intervals, require weekly or monthly maintenance to maintain and test those levels.
Current test devices use a measured pressure differential, whereas Uscom’s test will use ultrasonic calibration, along with software that accompanies the device.
Uscom’s device is patented protected and was developed at the company’s research and development centre in Budapest.
Recently, the medical equipment market has been flooded with new test devices as the global medical equipment supply chain reacts to the COVID-19 pandemic. But the SpiroSonic Ventitest device the company has produced has been in testing and production for 15 years, giving a high degree of confidence in its efficacy
The Executive Chair of Uscom, Professor Rob Phillips, said the devices the company had developed would set new standards of accuracy and cost-effectiveness for COVID-19 tests.
“The Ventitest will be sold into hospitals, respiratory device manufacturers and home consumers across the world, all of which depend on accurate calibration of their respiratory devices for effective operation and optimal clinical outcomes,” Rob explained.
“The global medical ventilators market is one of the fastest-growing segments in medical devices, and while it’s not difficult to manufacture ventilators, ventilator calibration requires technology with high levels of precision, and our ultrasonic sensors have been in development and clinical use for over 15 years,” he continued.
“For Uscom this is a rational business expansion; specialising our own patented protected technologies into new products for a rapidly expanding market and unprecedented global needs,” Rob commented.
Uscom shares are in the green today, trading 1.16 per cent higher for 21.8 cents at 1:28 pm AEST.
